Aligos Therapeutics, Inc.: Parkman Healthcare Partners LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Parkman Healthcare Partners LLC disclosed a stake exceeding 5% in Aligos Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000919574-26-007697). The filing signals that the healthcare-focused investor has crossed the key 5% beneficial ownership threshold, making it a reportable large shareholder in the clinical-stage biopharmaceutical company. The exact number of shares and percentage held were not specified in the headline disclosure. Investors will watch for further detail on the position's size and any subsequent 13G amendments, which could indicate whether Parkman intends a passive or more active role.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aligos Therapeutics, Inc., Parkman Healthcare Partners LLC